- Home
- VEL vs SVRA Comparison
VEL vs SVRA Comparison
Compare VEL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- SVRA
- Stock Information
- Founded
- VEL 2004
- SVRA 2007
- Country
- VEL United States
- SVRA United States
- Employees
- VEL N/A
- SVRA N/A
- Industry
- VEL Finance: Consumer Services
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- SVRA Health Care
- Exchange
- VEL Nasdaq
- SVRA Nasdaq
- Market Cap
- VEL 602.1M
- SVRA 527.2M
- IPO Year
- VEL 2020
- SVRA N/A
- Fundamental
- Price
- VEL $19.16
- SVRA $3.16
- Analyst Decision
- VEL Buy
- SVRA Buy
- Analyst Count
- VEL 5
- SVRA 7
- Target Price
- VEL $21.20
- SVRA $5.57
- AVG Volume (30 Days)
- VEL 99.6K
- SVRA 1.3M
- Earning Date
- VEL 08-07-2025
- SVRA 08-13-2025
- Dividend Yield
- VEL N/A
- SVRA N/A
- EPS Growth
- VEL 26.95
- SVRA N/A
- EPS
- VEL 2.22
- SVRA N/A
- Revenue
- VEL $195,592,000.00
- SVRA N/A
- Revenue This Year
- VEL N/A
- SVRA N/A
- Revenue Next Year
- VEL $32.82
- SVRA N/A
- P/E Ratio
- VEL $8.65
- SVRA N/A
- Revenue Growth
- VEL 44.29
- SVRA N/A
- 52 Week Low
- VEL $16.12
- SVRA $1.89
- 52 Week High
- VEL $20.98
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- VEL 65.99
- SVRA 71.42
- Support Level
- VEL $18.61
- SVRA $2.92
- Resistance Level
- VEL $19.19
- SVRA $3.28
- Average True Range (ATR)
- VEL 0.46
- SVRA 0.21
- MACD
- VEL 0.18
- SVRA 0.04
- Stochastic Oscillator
- VEL 96.66
- SVRA 85.88
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.